Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven Stage IIIB or IV bronchioloalveolar
non-small cell lung carcinoma -incompletely resected or unresectable -tumors may be
multifocal or diffuse -measurable or evaluable disease required No prior brain metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: SWOG 0-2 Life Expectancy:
Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than institutional upper limit of
normal (ULN) SGOT no greater than 2 times ULN Renal: Creatinine no greater than
institutional ULN OR creatinine clearance at least 50 mL/min Other: Not pregnant or
nursing Effective contraceptive method used while on study No prior malignancies allowed,
except: basal or squamous cell skin cancer in situ cervical cancer Stage I or II cancer
which is in remission Any cancer from which patients have been disease free for 5 years

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for lung cancer
Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No
prior radiation therapy (including palliative radiotherapy) Surgery: Prior surgery is
allowed